Chemotherapy

Chemotherapy

v/pmc/articles/PMC3658440" class="external text" rel="nofollow">"Nedaplatin: a cisplatin derivative in cancer chemotherapy". Cancer management and research 5: 67–76.  
  • ^ Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM; Estey; Appelbaum; Lo-Coco; Schiffer; Larson; Burnett; Kantarjian (17 September 2012). "Gemtuzumab Ozogamicin: Time to Resurrect?" (PDF). Journal of Clinical Oncology 30 (32): 3921–3923.  
  • ^ Lehnert M, Ludwig H, Zojer N; Ludwig; Zojer (February 2009). "Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma". OncoTargets and therapy 2: 199–208.  
  • ^ Cheson BD (2005). "The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.". BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy 19 (5): 309–22.  
  • ^ Nabhan C, Kay NE; Kay; Chadi Nabhan (March 2011). "The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia". Clinical Medicine Insights. Oncology 5: 45–53.  
  • ^ Osterborg A (March 2010). "Ofatumumab, a human anti-CD20 monoclonal antibody.". Expert Opinion on Biological Therapy 10 (3): 439–49.  
  • ^ Sanford M, McCormack PL; McCormack (May 2010). "Ofatumumab". Drugs 70 (8): 1013–1019.  
  • ^ Davies AJ (28 May 2007). "Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab". Oncogene 26 (25): 3614–3628.  
  • ^ "Bexxar (tositumomab) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ "Gilotrif (afatinib)". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ "Zaltrap (ziv-aflibercept) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Escudier B, Gore M; Gore (2011). "Axitinib for the management of metastatic renal cell carcinoma". Drugs in R&D 11 (2): 113–26.  
  • ^ "Bosulif (bosutinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Amsberg GK, Koschmieder S; Koschmieder (March 2013). "Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia". OncoTargets and Therapy 6: 99–106.  
  • ^ "Xalkori (crizotinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Forde PM, Rudin CM; Rudin (June 2012). "Crizotinib in the treatment of non-small-cell lung cancer". Expert opinion on pharmacotherapy 13 (8): 1195–201.  
  • ^ Frampton JE (28 November 2013). "Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer". Drugs 73 (18): 2031–2051.  
  • ^ Rothschild, SI; Gautschi, O (September 2013). "Crizotinib in the Treatment of Non–Small-Cell Lung Cancer". Clinical Lung Cancer 14 (5): 473–480.  
  • ^ Roskoski R (September 2013). "The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders". Expert Opinion on Drug Discovery 8 (9): 1165–1179.  
  • ^ "Iclusig (ponatinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Price KE, Saleem N, Lee G, Steinberg M; Saleem; Lee; Steinberg (August 2013). "Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia". OncoTargets and therapy 6: 1111–8.  
  • ^ "Stivarga (regorafenib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Strumberg D, Schultheis B; Schultheis (June 2012). "Regorafenib for cancer". Expert Opinion on Investigational Drugs 21 (6): 879–889.  
  • ^ Aprile G, Macerelli M, Giuliani F; MacErelli; Giuliani (23 February 2013). "Regorafenib for Gastrointestinal Malignancies". BioDrugs 27 (3): 213–224.  
  • ^ Shahda S, Saif MW; Saif (May 2013). "Regorafenib: from bench to bedside in colorectal cancer". Expert Review of Clinical Pharmacology 6 (3): 243–248.  
  • ^ "Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 10 February 2014. 
  • ^ "JAKAVI® Ruxolitinib" (PDF). TGA eBusiness Services. Novartis Pharmaceuticals Australia Pty Limited. 21 January 2014. 
  • ^ Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN; Silver; Komrokji; Mesa; Tacke; Harrison (December 2013). "Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects" (PDF). Clinical Lymphoma Myeloma and Leukemia 13 (6): 638–645.  
  • ^ Vaddi K, Sarlis NJ, Gupta V; Sarlis; Gupta (November 2012). "Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis". Expert Opinion on Pharmacotherapy 13 (16): 2397–2407.  
  • ^ "Vandetanib dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ "Targretin (bexarotene) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Matthay KK (3 December 2012). "Targeted Isotretinoin in Neuroblastoma: Kinetics, Genetics, or Absorption". Clinical Cancer Research 19 (2): 311–313.  
  • ^ "Amnesteem, Claravis (isotretinoin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ "Isotretinoin 20mg capsules - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Alliance Pharmaceuticals. 12 April 2013. Retrieved 9 February 2014. 
  • ^ Miwako I, Kagechika H; Kagechika (August 2007). "Tamibarotene". Drugs of today (Barcelona, Spain: 1998) 43 (8): 563–8.  
  • ^ Fukasawa H, Nakagomi M, Yamagata N, Katsuki H, Kawahara K, Kitaoka K, Miki T, Shudo K; Nakagomi; Yamagata; Katsuki; Kawahara; Kitaoka; Miki; Shudo (2012). "Tamibarotene: a candidate retinoid drug for Alzheimer's disease". Biological & Pharmaceutical Bulletin 35 (8): 1206–12.  
  • ^ Takeuchi M (March 2006). "[Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia].". Gan to kagaku ryoho. Cancer & chemotherapy (in Japanese) 33 (3): 397–401.  
  • ^ "Istodax (romidepsin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 10 February 2014. 
  • ^ Bellos F, Mahlknecht U; Mahlknecht (November 2008). "Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients". Onkologie 31 (11): 629–33.  
  • ^ Blaheta RA, Nau H, Michaelis M, Cinatl J; Nau; Michaelis; Cinatl Jr (August 2002). "Valproate and valproate-analogues: potent tools to fight against cancer". Current medicinal chemistry 9 (15): 1417–33.  
  • ^ Blaheta RA, Cinatl J; Cinatl Jr (September 2002). "Anti-tumor mechanisms of valproate: a novel role for an old drug". Medicinal Research Reviews 22 (5): 492–511.  
  • ^ Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA; Candelaria; Perez-Plascencia; Perez-Cardenas; de la Cruz-Hernandez; Herrera (May 2008). "Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors". Cancer treatment reviews 34 (3): 206–22.  
  • ^ "Zolinza (vorinostat) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 10 February 2014. 
  • ^ "Ontak (denileukin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 February 2014. 
  • ^ Lansigan F, Stearns DM, Foss F; Stearns; Foss (February 2010). "Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma". Cancer Management and Research 2: 53–59.  
  • ^ Manoukian G, Hagemeister F; Hagemeister (November 2009). "Denileukin diftitox: a novel immunotoxin". Expert Opinion on Biological Therapy 9 (11): 1445–1451.  
  • ^ Kaminetzky D, Hymes KB; Hymes (December 2008). "Denileukin diftitox for the treatment of cutaneous T-cell lymphoma". Biologics: Targets & Therapy 2 (4): 717–724.  
  • ^ Top 10 best-selling cancer drugs of 2013; May 29, 2014
  • Bibliography

    • Rachel Airley (2009). Cancer chemotherapy. Wiley-Blackwell.  
    • Wood, Miriam; David Brighton (2005). The Royal Marsden Hospital handbook of cancer chemotherapy: a guide for the multidisciplinary team. St. Louis, Mo: Elsevier Churchill Livingstone.  
    • Fergus Macbeth; Hanna, Louise; Crosby, Tom (2008). Practical clinical oncology. Cambridge, UK: Cambridge University Press. 
    • Perry, Michael J. (2008). The Chemotherapy source book. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 
    • Faguet, Guy B. (2005). The War on Cancer. Springer. p. 71.  
    • Hirsch J (September 2006). "An anniversary for cancer chemotherapy". JAMA 296 (12): 1518–20.  
    • Huang, Elbert S. (2000). Internal medicine: handbook for clinicians, resident survival guide. Arlington, VA: Scrub Hill Press. p. 130.  
    • Randall, [edited by] William J. Hoskins, Carlos A. Perez, Robert C. Young, Richard R. Barakat, Maurie Markman, Marcus E. (2005). Principles and practice of gynecologic oncology (4. ed.). Baltimore, Md.: Lippincott Williams & Wilkins. pp. 93–94.  

    External links

    • Search for chemotherapy trials
    • American Cancer Society - Chemotherapy
    • Chemotherapy side effects